FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205113219> ?p ?o ?g. }

• W3205113219 endingPage "1049" @default.
• W3205113219 startingPage "1049" @default.
• W3205113219 abstract "Background: Patients with severe hemophilia often present with painful joint and soft tissue bleeding which may restrict them from their daily activities. The current standard of care still relies on a regular prophylactic factor VIII (FVIII), which has a high daily treatment burden. Recently, rurioctocog alfa pegol, a third-generation recombinant FVIII with a modification in its polyethylene glycol (PEG) component, has been developed. Several trials have studied this synthetic drug as bleeding prophylaxis in severe hemophilia A. This study aims to evaluate the efficacy, safety, and immunogenicity of rurioctocog alfa pegol for previously treated patients with severe hemophilia A. Methods: This study was conducted in conformity with the PRISMA guidelines. Data were retrieved from PubMed, Scopus, Cochrane Library, Wiley Online Library, and CINAHL (via EBSCOhost). Study qualities were assessed using the Methodological Index for Non-Randomized Studies (MINORS) and Modified Jadad scales. Results: Four studies involving 517 previously treated severe hemophilia A patients were included in this study. The pooled mean of total annualized bleeding rate (ABR) and hemostatic efficacy was 2.59 (95% CI = 2.04-3.14) and 92% (95% CI = 85%-97%), respectively. Only 30 (2.3%) non-serious and one (1.4%) serious adverse events were considered related to rurioctocog alfa pegol treatment. At the end of the studies, no development of FVIII inhibitory antibodies was observed. None of the developed binding antibodies to FVIII, PEG-FVIII, or PEG was correlated to the treatment efficacy and safety. Conclusions: Despite the limited availability of direct comparison studies, our analyses indicate that rurioctocog alfa pegol could serve as a safe and effective alternative for bleeding prophylaxis in previously treated hemophilia A patients. Moreover, it appears to have low immunogenicity, which further increases the safety profile of the drug in such clinical conditions." @default.
• W3205113219 created "2021-10-25" @default.
• W3205113219 creator A5019015403 @default.
• W3205113219 creator A5031590696 @default.
• W3205113219 creator A5071316963 @default.
• W3205113219 creator A5076722458 @default.
• W3205113219 creator A5078915740 @default.
• W3205113219 creator A5085481071 @default.
• W3205113219 date "2021-10-15" @default.
• W3205113219 modified "2023-10-03" @default.
• W3205113219 title "Efficacy safety and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials" @default.
• W3205113219 cites W1586003096 @default.
• W3205113219 cites W1607497674 @default.
• W3205113219 cites W1623696825 @default.
• W3205113219 cites W1974965024 @default.
• W3205113219 cites W1990811757 @default.
• W3205113219 cites W2013607072 @default.
• W3205113219 cites W2016959016 @default.
• W3205113219 cites W2017044005 @default.
• W3205113219 cites W2033176757 @default.
• W3205113219 cites W2046585038 @default.
• W3205113219 cites W2049032499 @default.
• W3205113219 cites W2049172876 @default.
• W3205113219 cites W2072339301 @default.
• W3205113219 cites W2080529015 @default.
• W3205113219 cites W2085306050 @default.
• W3205113219 cites W2168608087 @default.
• W3205113219 cites W2274569134 @default.
• W3205113219 cites W2473802130 @default.
• W3205113219 cites W2550202055 @default.
• W3205113219 cites W2557234475 @default.
• W3205113219 cites W2562603171 @default.
• W3205113219 cites W2591571157 @default.
• W3205113219 cites W2747199873 @default.
• W3205113219 cites W2766206296 @default.
• W3205113219 cites W2779779172 @default.
• W3205113219 cites W2792416539 @default.
• W3205113219 cites W2796766105 @default.
• W3205113219 cites W2804768912 @default.
• W3205113219 cites W2807217137 @default.
• W3205113219 cites W2935117038 @default.
• W3205113219 cites W2965056463 @default.
• W3205113219 cites W2967535150 @default.
• W3205113219 cites W2977824986 @default.
• W3205113219 cites W3037340949 @default.
• W3205113219 cites W3047046471 @default.
• W3205113219 cites W3096939226 @default.
• W3205113219 cites W4294215472 @default.
• W3205113219 doi "https://doi.org/10.12688/f1000research.73884.1" @default.
• W3205113219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35136579" @default.
• W3205113219 hasPublicationYear "2021" @default.
• W3205113219 type Work @default.
• W3205113219 sameAs 3205113219 @default.
• W3205113219 citedByCount "2" @default.
• W3205113219 countsByYear W32051132192023 @default.
• W3205113219 crossrefType "journal-article" @default.
• W3205113219 hasAuthorship W3205113219A5019015403 @default.
• W3205113219 hasAuthorship W3205113219A5031590696 @default.
• W3205113219 hasAuthorship W3205113219A5071316963 @default.
• W3205113219 hasAuthorship W3205113219A5076722458 @default.
• W3205113219 hasAuthorship W3205113219A5078915740 @default.
• W3205113219 hasAuthorship W3205113219A5085481071 @default.
• W3205113219 hasBestOaLocation W32051132191 @default.
• W3205113219 hasConcept C126322002 @default.
• W3205113219 hasConcept C142724271 @default.
• W3205113219 hasConcept C159654299 @default.
• W3205113219 hasConcept C168563851 @default.
• W3205113219 hasConcept C197934379 @default.
• W3205113219 hasConcept C203014093 @default.
• W3205113219 hasConcept C204787440 @default.
• W3205113219 hasConcept C27081682 @default.
• W3205113219 hasConcept C2776215756 @default.
• W3205113219 hasConcept C2776478404 @default.
• W3205113219 hasConcept C2779134260 @default.
• W3205113219 hasConcept C2780132546 @default.
• W3205113219 hasConcept C2780868878 @default.
• W3205113219 hasConcept C535046627 @default.
• W3205113219 hasConcept C71924100 @default.
• W3205113219 hasConcept C95190672 @default.
• W3205113219 hasConceptScore W3205113219C126322002 @default.
• W3205113219 hasConceptScore W3205113219C142724271 @default.
• W3205113219 hasConceptScore W3205113219C159654299 @default.
• W3205113219 hasConceptScore W3205113219C168563851 @default.
• W3205113219 hasConceptScore W3205113219C197934379 @default.
• W3205113219 hasConceptScore W3205113219C203014093 @default.
• W3205113219 hasConceptScore W3205113219C204787440 @default.
• W3205113219 hasConceptScore W3205113219C27081682 @default.
• W3205113219 hasConceptScore W3205113219C2776215756 @default.
• W3205113219 hasConceptScore W3205113219C2776478404 @default.
• W3205113219 hasConceptScore W3205113219C2779134260 @default.
• W3205113219 hasConceptScore W3205113219C2780132546 @default.
• W3205113219 hasConceptScore W3205113219C2780868878 @default.
• W3205113219 hasConceptScore W3205113219C535046627 @default.
• W3205113219 hasConceptScore W3205113219C71924100 @default.
• W3205113219 hasConceptScore W3205113219C95190672 @default.
• W3205113219 hasLocation W32051132191 @default.
• W3205113219 hasLocation W32051132192 @default.
• W3205113219 hasOpenAccess W3205113219 @default.

• next